Cell and Gene Therapy Today—June 4, 2026

This week’s Cell and Gene Therapy update highlights regulatory progress, early clinical activity, in vivo cell engineering advances, gene therapy development milestones, and strategic collaborations across oncology, neurology, and vascular disease.

In Today’s Newsletter

Dive deeper

💊 Immatics IMA203CD8 PRAME cell therapy at ASCO 2026 [1] [US • 30 May 2026]

https://www.globenewswire.com/news-release/2026/05/30/3303876/0/en/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting.html
Context: Immatics reported ongoing Phase 1 data for IMA203CD8 in gynecologic cancers and synovial sarcoma.
Key point: The company reported objective responses, complete responses, and manageable tolerability across PRAME-positive solid tumors.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Iovance IOV-5001 IL-12 tethered TIL IND clearance [2] [US • 01 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/01/3304233/0/en/iovance-biotherapeutics-announces-clearance-of-investigational-new-drug-ind-application-for-il-12-tethered-til-therapy-iov-5001.html
Context: IOV-5001 is a next-generation IL-12 tethered TIL therapy for solid tumors.
Key point: FDA cleared the IND for a Phase 1/2 basket trial, with enrollment planned in H2 2026.
Implication: Signals pipeline investment and modality expansion.

🧫 Kelonia KLN-1010 in vivo BCMA CAR-T data [3] [US • 31 May 2026]

https://keloniatx.com/kelonia-therapeutics-presents-updated-first-in-human-data-from-phase-1-inmmycar-study-of-kln-1010-in-vivo-bcma-car-t-therapy-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting/
Context: KLN-1010 is an in vivo BCMA CAR-T therapy studied in relapsed/refractory multiple myeloma.
Key point: Kelonia reported updated first-in-human Phase 1 responses without lymphodepleting chemotherapy.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🩸 Legend Biotech LB2501 in vivo CAR-T data [4] [EU • 02 Jun 2026]

https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-announces-late-breaking-oral-presentation-eha
Context: LB2501 is an in vivo CD19/CD20 dual-targeting CAR-T therapy for R/R B-NHL.
Key point: Legend reported early Phase 1 activity and said data will be presented at EHA 2026.
Implication: Signals pipeline investment and modality expansion.

📄 FDA draft guidance on gene therapy prior knowledge [5] [US • 02 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/02/3305422/0/en/fda-issues-draft-guidance-to-help-accelerate-cell-and-gene-therapies-for-patients.html
Context: FDA issued draft guidance for human gene therapy products using genome editing in somatic cells.
Key point: The draft describes how sponsors may use existing public and platform knowledge in submissions.
Implication: May expand screening, initiation, and follow-up at scale.

🧠 Trogenix TGX-007 first patient dosed in GBM [6] [UK–US • 28 May 2026]

https://www.globenewswire.com/news-release/2026/05/28/3302647/0/en/trogenix-doses-first-patient-in-phase-i-ii-clinical-trial-of-tgx-007-gene-therapy-for-glioblastoma.html
Context: TGX-007 is a dual-payload AAV gene therapy in the Phase I/II ADePT trial for glioblastoma.
Key point: Trogenix dosed the first patient, with UK and US trial sites open.
Implication: May influence prescriber choice and payer reviews pending full data.

🇨🇳 Helixmith and Northland NL003 China approval [7] [China • 01 Jun 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31861
Context: NL003 is a non-viral plasmid DNA gene therapy for chronic limb-threatening ischemia.
Key point: Northland Biotech received NMPA marketing approval for NL003, based on Helixmith platform technology.
Implication: Introduces competition that may affect pricing and formulary access.

🤝 Solid Biosciences and NanoMosaic co-marketing pact [8] [US • 02 Jun 2026]

https://www.prnewswire.com/news-releases/solid-biosciences-and-nanomosaic-announce-co-marketing-agreement-to-advance-gene-therapy-delivery-and-analytics-302787988.html
Context: Solid’s POLARIS-101 capsid and NanoMosaic’s Tessie platform target delivery and AAV analytics.
Key point: The companies announced a co-marketing agreement for gene therapy delivery, measurement, and regulatory readiness.
Implication: Signals pipeline investment and modality expansion.

🧬 Voyager VY1706 tau-targeted gene therapy IND clearance [9] [US • 01 Jun 2026]

https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-receives-fda-ind-clearance-vy1706-first-gene-therapy
Context: VY1706 is an IV-delivered, brain-targeted gene therapy designed to reduce tau production in Alzheimer’s disease.
Key point: FDA cleared the IND, enabling a trial in adults with early Alzheimer’s disease.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

In vivo CAR-T momentum continued across BCMA, CD19/CD20, and solid-tumor TIL approaches.
FDA activity suggests regulators are trying to reduce duplicated work in gene therapy development.
AAV delivery and analytics remain central bottlenecks for scalability, dosing, and product characterization.
Oncology remains the dominant clinical focus, but Alzheimer’s disease and ischemia updates broaden the modality map.
China’s NL003 approval highlights regional commercialization paths for non-viral gene therapy.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Rare Disease archive on our research hub page

FAQ

What did Immatics report for IMA203CD8?

Immatics reported Phase 1 activity for IMA203CD8, a PRAME-targeted TCR T-cell therapy, in gynecologic cancers and synovial sarcoma. The company also described tolerability as manageable [1].

What is Iovance’s IOV-5001?

IOV-5001 is an IL-12 tethered TIL therapy designed for solid tumors. FDA cleared its IND for a Phase 1/2 basket trial, with enrollment planned in H2 2026 [2].

How is Kelonia’s KLN-1010 different from conventional CAR-T?

KLN-1010 is designed as an in vivo BCMA CAR-T, generating CAR-T cells inside the patient. Kelonia reported Phase 1 RRMM data without lymphodepleting chemotherapy [3].

What is Legend Biotech presenting at EHA 2026?

Legend Biotech said it will present initial Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy in relapsed/refractory B-cell NHL [4].

What does the FDA draft guidance cover?

The draft guidance explains how gene therapy sponsors may use existing public information and platform knowledge across CMC, nonclinical, and clinical areas [5].

Why is Voyager’s VY1706 notable?

Voyager said FDA cleared VY1706 as a tau-targeted gene therapy for early Alzheimer’s disease. The planned trial will assess safety and tau-related biomarkers [9].

Entities / Keywords

Immatics: IMA203CD8, PRAME, TCR T-cell therapy, ovarian cancer, uterine cancer, synovial sarcoma, ASCO 2026
Iovance Biotherapeutics: IOV-5001, IL-12 tethered TIL, solid tumors, IND, Phase 1/2
Kelonia Therapeutics: KLN-1010, in vivo BCMA CAR-T, inMMyCAR, RRMM, multiple myeloma
Legend Biotech: LB2501, CD19/CD20, in vivo CAR-T, B-NHL, EHA 2026, TaVec
FDA, CBER: draft guidance, prior knowledge, genome editing, CMC, INTERACT, pre-IND
Trogenix: TGX-007, ADePT, AAV gene therapy, glioblastoma, synthetic super-enhancer
Helixmith, Northland Biotech: NL003, Engensis, VM202, plasmid DNA, CLI, NMPA
Solid Biosciences, NanoMosaic: POLARIS-101, AAV-SLB101, Tessie, AAV analytics, AMT designation
Voyager Therapeutics: VY1706, tau, MAPT, TRACER AAV capsid, Alzheimer’s disease